A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Summary

This is a randomized, double-blind, placebo-controlled Phase Ib/IIa study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of XW001 inhalation in children with RSV infection in China

Timeline

Start

2023-04-20

Primary completion

2023-10-10

Completion

2024-01-08

Drugs

Indications